Recent perspectives on the delivery of biologics to back of the eye

References

• The global economic cost of visual impairment; 2014. Available from: http://www.icoph.org/resources/146/The-Global-Economic-Cost-of-Visual-Impairment.html
   Google Scholar
• Boddu SH, Gupta H, Patel S. Drug delivery to the back of the eye following topical administration: an update on research and patenting activity. Recent Pat Drug Deliv Formul. 2014;8(1):27–36.
   PubMedGoogle Scholar
• Gaudana R, Ananthula HK, Parenky A, et al. Ocular drug delivery. AAPS J. 2010;12(3):348–360.
   PubMed Web of Science ®Google Scholar
• Zajac-Pytrus HM, Pilecka A, Turno-Krecicka A, et al. The dry form of age-related macular degeneration (amd): the current concepts of pathogenesis and prospects for treatment. Adv Clin Exp Med Off Organ Wroclaw Med Univ. 2015;24(6):1099–1104.
   PubMed Web of Science ®Google Scholar
• Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vision. 2015;2:17.
   Google Scholar
• Wiersbitzky S, Ballke EH, Burghardt R, et al. long-term study of various immunologic functions in children with chronic nonspecific lung diseases. Z Erkr Atmungsorgane. 1985;164(3):241–253.
   PubMedGoogle Scholar
• Mohamed R, El-Remessy AB. Imbalance of the nerve growth factor and its precursor: implication in diabetic retinopathy. J Clin Exp Ophthalmol. 2015;6:5.
   Google Scholar
• Fogli S, Mogavero S, Egan CG, et al. Pathophysiology and pharmacological targets of vegf in diabetic macular edema. Pharmacol Res. 2016;103:149–157.
   PubMed Web of Science ®Google Scholar
• Takeuchi M. A systematic review of biologics for the treatment of noninfectious uveitis. Immuno Ther. 2013;5(1):91–102.
   PubMed Web of Science ®Google Scholar
• Posarelli C, Arapi I, Figus M, et al. Biologic agents in inflammatory eye disease. J Ophthalmic Vis Res. 2011;6(4):309–316. .
   PubMedGoogle Scholar
• McKibbin M, Devonport H, Gale R, et al. Aflibercept in wet amd beyond the first year of treatment: recommendations by an expert roundtable panel. Eye. 2015;29(Suppl 1):S1–S11.
   PubMed Web of Science ®Google Scholar
• Heier JS, Bressler NM, Avery RL, et al. Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice. JAMA Ophthalmol. 2016;134(1):95–99.
   PubMed Web of Science ®Google Scholar
• Bressler NM, Varma R, Mitchell P, et al. Effect of ranibizumab on the decision to drive and vision function relevant to driving in patients with diabetic macular edema: report from restore, ride, and rise trials. JAMA Ophthalmol. 2016;134(2):160–166.
   PubMed Web of Science ®Google Scholar
• Gibson JM, McGinnigle S. Diabetes: intravitreous ranibizumab for proliferative diabetic retinopathy. Nat Rev Endocrinol. 2016;12(3):130–131.
   PubMed Web of Science ®Google Scholar
• Rush RB, Rush SW. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration with an incomplete posterior vitreous detachment. Asia-Pacific J Ophthalmol. 2016;5(3):171–175.
   PubMed Web of Science ®Google Scholar
• Chin-Yee D, Eck T, Fowler S, et al. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol. 2016;100:914–917.
   PubMed Web of Science ®Google Scholar
• Amadio M, Govoni S, Pascale A. Targeting vegf in eye neovascularization: What’s new? A comprehensive review on current therapies and oligonucleotide-based interventions under development. Pharmacol Res. 2016;103:253–269.
   PubMed Web of Science ®Google Scholar
• Ho M, Liu DT, Lam DS, et al. Retinal vein occlusions, from basics to the latest treatment. Retina. 2016;36(3):432–448.
   PubMed Web of Science ®Google Scholar
• Cholkar K, Patel A, Vadlapudi AD, et al. Novel nanomicellar formulation approaches for anterior and posterior segment ocular drug delivery. Recent Pat Nanomed. 2012;2(2):82–95.
   PubMedGoogle Scholar
• Vaishya RD, Mandal A, Patel S, et al. Extended release microparticle-in-gel formulation of octreotide: effect of polymer type on acylation of peptide during in vitro release. Int J Pharm. 2015;496(2):676–688.
   PubMed Web of Science ®Google Scholar
• Vaishya RD, Mandal A, Gokulgandhi M, et al. Reversible hydrophobic ion-paring complex strategy to minimize acylation of octreotide during long-term delivery from plga microparticles. Int J Pharm. 2015;489(1–2):237–245.
   PubMed Web of Science ®Google Scholar
• Comparison of Age-related Macular Degeneration Treatments Trials Research G, Maguire MG, Martin DF, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751–1761.
   Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase iii randomized trials: rise and ride. Ophthalmology. 2012;119(4):789–801.
   PubMed Web of Science ®Google Scholar
• Jackson TL, Desai R, Simpson A, et al. Epimacular brachytherapy for previously treated neovascular age-related macular degeneration (merlot): a phase 3 randomized controlled trial. Ophthalmology. 2016;123:1287–1296.
   PubMed Web of Science ®Google Scholar
• Tadayoni R, Waldstein SM, Boscia F, et al. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of brighter. Ophthalmology. 2016;123:1332–1344.
   PubMed Web of Science ®Google Scholar
• Pfau M, Fassnacht-Riederle HM, Freiberg FJ, et al. switching therapy from ranibizumab and/or bevacizumab to aflibercept in neovascular age-related macular degeneration (amd): one-year results. Klin Monbl Augenheilkd. 2016;233(8):945–950.
   PubMed Web of Science ®Google Scholar
• Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–2254.
   PubMed Web of Science ®Google Scholar
• Sivaprasad S, Prevost AT, Bainbridge J, et al. Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym clarity): a multicentre phase iib randomised active-controlled clinical trial. BMJ Open. 2015;5(9):e008405.
   PubMed Web of Science ®Google Scholar
• Comparison of Age-related Macular Degeneration Treatments Trials Research G, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398.
   PubMed Web of Science ®Google Scholar
• Shiragami C, Ono A, Kobayashi M, et al. Effect of switching therapy to pegaptanib in eyes with the persistent cases of exudative age-related macular degeneration. Medicine. 2014;93(18):e116.
   PubMed Web of Science ®Google Scholar
• Good TJ, Kimura AE, Mandava N, et al. Sustained elevation of intraocular pressure after intravitreal injections of anti-vegf agents. Br J Ophthalmol. 2011;95(8):1111–1114.
   PubMed Web of Science ®Google Scholar
• Hoang QV, Tsuang AJ, Gelman R, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina. 2013;33(1):179–187.
   PubMed Web of Science ®Google Scholar
• Yu AL, Seidensticker F, Schaumberger M, et al. Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab. Clin Ophthalmol. 2014;8:743–747.
   PubMedGoogle Scholar
• Patel SP, Vaishya R, Pal D, et al. Novel pentablock copolymer-based nanoparticulate systems for sustained protein delivery. AAPS Pharm Sci Tech. 2015;16(2):327–343.
   PubMed Web of Science ®Google Scholar
• Ozaki T, Nakazawa M, Yamashita T, et al. Delivery of topically applied calpain inhibitory peptide to the posterior segment of the rat eye. PLoS One. 2015;10(6):e0130986.
   PubMed Web of Science ®Google Scholar
• Schopf LR, Popov AM, Enlow EM, et al. Topical ocular drug delivery to the back of the eye by mucus-penetrating particles. Transl Vis Sci Technol. 2015;4(3):11.
   PubMed Web of Science ®Google Scholar
• Cholkar K, Gilger BC, Mitra AK. Topical, aqueous, clear cyclosporine formulation design for anterior and posterior ocular delivery. Transl Vis Sci Technol. 2015;4(3):1. .
   PubMed Web of Science ®Google Scholar
• Moisseiev E, Waisbourd M, Ben-Artsi E, et al. Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes. Graefe’s Archive for Clin and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie. 2014;252(2):331–337.
   PubMed Web of Science ®Google Scholar
• Davis BM, Normando EM, Guo L, et al. Topical delivery of avastin to the posterior segment of the eye in vivo using annexin a5-associated liposomes. Small. 2014;10(8):1575–1584.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Ebmeier SE, Sutherland WM, et al. Potential penetration of topical ranibizumab (lucentis) in the rabbit eye. Eye. 2011;25(11):1504–1511.
   PubMed Web of Science ®Google Scholar
• Ford KM, Saint-Geniez M, Walshe TE, et al. Expression and role of vegf–a in the ciliary body. Invest Ophthalmol Vis Sci. 2012;53(12):7520–7527.
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653–2664.
   PubMed Web of Science ®Google Scholar
• Shah CA. Diabetic retinopathy: a comprehensive review. Indian J Med Sci. 2008;62(12):500–519.
   PubMedGoogle Scholar
• Simo R, Carrasco E, Garcia-Ramirez M, et al. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2006;2(1):71–98.
   PubMedGoogle Scholar
• Rotsos TG, Moschos MM. Cystoid macular edema. Clin Ophthalmol. 2008;2(4):919–930.
   PubMedGoogle Scholar
• Marashi A. Using anti-vegf in diabetic retinopathy. Adv Ophthalmol Vis Syst. 2016;4:4.
   Google Scholar
• Crawford TN, Alfaro DV III, Kerrison JB, et al. Diabetic retinopathy and angiogenesis. Curr Diabetes Rev. 2009;5(1):8–13.
   PubMedGoogle Scholar
• Gupta N, Mansoor S, Sharma A, et al. Diabetic retinopathy and vegf. Open Ophthalmol J. 2013;7:4–10.
   PubMedGoogle Scholar
• Kim JH, Kim JH, Yu YS, et al. Blockade of angiotensin ii attenuates vegf-mediated blood-retinal barrier breakdown in diabetic retinopathy. J Cereb Blood Flow Metab. 2009;29(3):621–628.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yan H. Microrna-126 contributes to niaspan treatment induced vascular restoration after diabetic retinopathy. Sci Rep. 2016;6:26909.
   PubMed Web of Science ®Google Scholar
• Nowak JZ. Age-related macular degeneration (amd): pathogenesis and therapy. Pharmacol Rep. 2006;58(3):353–363.
   PubMed Web of Science ®Google Scholar
• Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs. 2008;68(8):1029–1036.
   PubMed Web of Science ®Google Scholar
• Green WR, McDonnell PJ, Yeo JH. Pathologic features of senile macular degeneration. 1985. Retina. 2005;25(5 Suppl):615–627.
   PubMedGoogle Scholar
• Bressler SB, Silva JC, Bressler NM, et al. Clinicopathologic correlation of occult choroidal neovascularization in age-related macular degeneration. 1992. Retina. 2005;25(5 Suppl):827–832.
   PubMedGoogle Scholar
• Agarwal A, Rhoades WR, Hanout M, et al. Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development. Clin Ophthalmology. 2015;9:1001–1015.
   PubMed Web of Science ®Google Scholar
• Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43(1):3–18.
   PubMed Web of Science ®Google Scholar
• Kon CH, Asaria RH, Occleston NL, et al. Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study. Br J Ophthalmol. 2000;84(5):506–511.
   PubMed Web of Science ®Google Scholar
• Sadaka A, Giuliari GP. Proliferative vitreoretinopathy: current and emerging treatments. Clin Ophthalmol. 2012;6:1325–1333.
   PubMedGoogle Scholar
• Kwon OW, Roh MI, Song JH. Retinal detachment and proliferative vitreoretinopathy. In: Retinal diseases amenable to pharmacotherapy. Dev Ophthalmol. 2016;55;154–162.
   Google Scholar
• Doughty MJ, Zaman ML. Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol. 2000;44(5):367–408.
   PubMed Web of Science ®Google Scholar
• Yi X, Wang Y, Yu FS. Corneal epithelial tight junctions and their response to lipopolysaccharide challenge. Invest Ophthalmol Vis Sci. 2000;41(13):4093–4100.
   PubMed Web of Science ®Google Scholar
• Mitic LL, Van Itallie CM, Anderson JM. Molecular physiology and pathophysiology of tight junctions i. Tight junction structure and function: lessons from mutant animals and proteins. Am J Physiol Gastrointest Liver Physiol. 2000;279(2):G250–254.
   PubMed Web of Science ®Google Scholar
• Edward A, Prausnitz MR. Predicted permeability of the cornea to topical drugs. Pharm Res. 2001;18(11):1497–1508.
   PubMed Web of Science ®Google Scholar
• Van Haeringen NJ, Glasius E. Lysosomal hydrolases in tears and the lacrimal gland: effect of acetylsalicylic acid on the release from the lacrimal gland. Invest Ophthalmol Vis Sci. 1980;19(7):826–829.
   PubMed Web of Science ®Google Scholar
• Huang AJ, Tseng SC, Kenyon KR. Paracellular permeability of corneal and conjunctival epithelia. Invest Ophthalmol Vis Sci. 1989;30(4):684–689.
   PubMed Web of Science ®Google Scholar
• Kim SH, Galban CJ, Lutz RJ, et al. Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol Vis Sci. 2007;48(2):808–814.
   PubMed Web of Science ®Google Scholar
• Nakao S, Hafezi-Moghadam A, Ishibashi T. Lymphatics and lymphangiogenesis in the eye. J Ophthalmol. 2012;2012:1–11.
   Web of Science ®Google Scholar
• Bellhorn RW. Permeability of blood-ocular barriers of neonatal and adult cats to fluorescein-labeled dextrans of selected molecular sizes. Invest Ophthalmol Vis Sci. 1981;21(2):282–290.
   PubMed Web of Science ®Google Scholar
• Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87(12):1479–1488.
   PubMed Web of Science ®Google Scholar
• Olsen TW, Edelhauser HF, Lim JI, et al. Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning. Invest Ophthalmol Vis Sci. 1995;36(9):1893–1903.
   PubMed Web of Science ®Google Scholar
• Maurice DM, Polgar J. Diffusion across the sclera. Exp Eye Res. 1977;25(6):577–582.
   PubMed Web of Science ®Google Scholar
• Wen H, Hao J, Li SK. Characterization of human sclera barrier properties for transscleral delivery of bevacizumab and ranibizumab. J Pharm Sci. 2013;102(3):892–903.
   PubMed Web of Science ®Google Scholar
• Pino RM, Essner E. Permeability of rat choriocapillaris to hemeproteins. Restriction of tracers by a fenestrated endothelium. J Histochem Cytochem Off J Histochem Soc. 1981;29(2):281–290.
   PubMed Web of Science ®Google Scholar
• Essner E, Gordon SR. Observations on the permeability of the choriocapillaris of the eye. Cell Tissue Res. 1983;231(3):571–577.
   PubMed Web of Science ®Google Scholar
• Pitkanen L, Ranta VP, Moilanen H, et al. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest Ophthalmol Vis Sci. 2005;46(2):641–646.
   PubMed Web of Science ®Google Scholar
• Jackson TL, Antcliff RJ, Hillenkamp J, et al. Human retinal molecular weight exclusion limit and estimate of species variation. Invest Ophthalmol Vis Sci. 2003;44(5):2141–2146.
   PubMed Web of Science ®Google Scholar
• Tao Y, Li XX, Jiang YR, et al. Diffusion of macromolecule through retina after experimental branch retinal vein occlusion and estimate of intraretinal barrier. Curr Drug Metab. 2007;8(2):151–156.
   PubMed Web of Science ®Google Scholar
• Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125i-labeled full-length and fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27(5):536–544.
   PubMed Web of Science ®Google Scholar
• Tojo K. A pharmacokinetic model for ocular drug delivery. Chem Pharm Bull. 2004;52(11):1290–1294.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (lucentis). Ophthalmology. 2007;114(12):2179–2182.
   PubMed Web of Science ®Google Scholar
• Fauser S, Kalbacher H, Alteheld N, et al. Pharmacokinetics and safety of intravitreally delivered etanercept. Graefe’s Archive for Clin and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie. 2004;242(7):582–586.
   PubMed Web of Science ®Google Scholar
• Iyer MN, He F, Wensel TG, et al. Intravitreal clearance of moxifloxacin. Trans Am Ophthalmol Soc. 2005;103:76–81, discussion 81–73.
   PubMedGoogle Scholar
• Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (avastin). Ophthalmology. 2007;114(5):855–859.
   PubMed Web of Science ®Google Scholar
• Xu L, Lu T, Tuomi L, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci. 2013;54(3):1616–1624.
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhufabv2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46(2):726–733.
   PubMed Web of Science ®Google Scholar
• Sinapis CI, Routsias JG, Sinapis AI, et al. Pharmacokinetics of intravitreal bevacizumab (avastin(r)) in rabbits. Clin Ophthalmol. 2011;5:697–704.
   PubMedGoogle Scholar
• Park SJ, Oh J, Kim YK, et al. Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-trap in a rabbit model. Eye. 2015;29(4):561–568.
   PubMed Web of Science ®Google Scholar
• Miyake T, Sawada O, Kakinoki M, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci. 2010;51(3):1606–1608.
   PubMed Web of Science ®Google Scholar
• Del Amo EM, Urtti A. Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data. Exp Eye Res. 2015;137:111–124.
   PubMed Web of Science ®Google Scholar
• Le KN, Gibiansky L, Good J, et al. A mechanistic pharmacokinetic/pharmacodynamic model of factor d inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy. J Pharmacol Exp Ther. 2015;355(2):288–296.
   PubMed Web of Science ®Google Scholar
• Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (nx1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res. 2000;17(12):1503–1510.
   PubMed Web of Science ®Google Scholar
• Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-vegf aptamer for ocular vascular disease. Nat Rev Drug Discovery. 2006;5(2):123–132.
   PubMed Web of Science ®Google Scholar
• Abdelkader H, Alany RG. Controlled and continuous release ocular drug delivery systems: pros and cons. Curr Drug Deliv. 2012;9(4):421–430.
   PubMed Web of Science ®Google Scholar
• Mishra GP, Bagui M, Tamboli V, et al. Recent applications of liposomes in ophthalmic drug delivery. J Drug Deliv. 2011;2011:1–14.
   Google Scholar
• Puglia C, Offerta A, Carbone C, et al. Lipid nanocarriers (lnc) and their applications in ocular drug delivery. Curr Med Chem. 2015;22(13):1589–1602.
   PubMed Web of Science ®Google Scholar
• Yellepeddi VK, Palakurthi S. Recent advances in topical ocular drug delivery. J Ocular Pharmacology Therapeutics: Official Journal Assoc Ocul Pharmacol Ther. 2016;32(2):67–82.
   PubMed Web of Science ®Google Scholar
• Hennig R, Goepferich A. Nanoparticles for the treatment of ocular neovascularizations. Eur J Pharmaceutics Biopharm: Official J Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik Ev. 2015;95(Pt B):294–306.
   Google Scholar
• Shah SS, Denham LV, Elison JR, et al. Drug delivery to the posterior segment of the eye for pharmacologic therapy. Expert Rev Ophthalmol. 2010;5(1):75–93.
   PubMedGoogle Scholar
• Pignatello R, Carbone C, Puglia C, et al. Ophthalmic applications of lipid-based drug nanocarriers: an update of research and patenting activity. Ther Deliv. 2015;6(11):1297–1318.
   PubMedGoogle Scholar
• Musumeci T, Bucolo C, Carbone C, et al. Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits. Int J Pharm. 2013;440(2):135–140.
   PubMed Web of Science ®Google Scholar
• MacDonald IM, Sauve Y, Sieving PA. Preventing blindness in retinal disease: ciliary neurotrophic factor intraocular implants. Can J Ophthalmol J Can D’ophtalmol. 2007;42(3):399–402.
   PubMed Web of Science ®Google Scholar
• Myles ME, Neumann DM, Hill JM. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev. 2005;57(14):2063–2079.
   PubMed Web of Science ®Google Scholar
• Hughes PM, Olejnik O, Chang-Lin JE, et al. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev. 2005;57(14):2010–2032.
   PubMed Web of Science ®Google Scholar
• Marano RJ, Wimmer N, Kearns PS, et al. Inhibition of in vitro vegf expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp Eye Res. 2004;79(4):525–535.
   PubMed Web of Science ®Google Scholar
• Yasin MN, Svirskis D, Seyfoddin A, et al. Implants for drug delivery to the posterior segment of the eye: a focus on stimuli-responsive and tunable release systems. J Controlled Release Off J Controlled Release Soc. 2014;196:208–221.
   PubMed Web of Science ®Google Scholar
• Rowe-Rendleman CL, Durazo SA, Kompella UB, et al. Drug and gene delivery to the back of the eye: from bench to bedside. Invest Ophthalmol Vis Sci. 2014;55(4):2714–2730.
   PubMed Web of Science ®Google Scholar
• Tucker BA, Mullins RF, Stone EM. Stem cells for investigation and treatment of inherited retinal disease. Hum Mol Genet. 2014;23(R1):R9–R16.
   PubMed Web of Science ®Google Scholar
• Wan C, Li F, Li H. Gene therapy for ocular diseases meditated by ultrasound and microbubbles (review). Mol Med Rep. 2015;12(4):4803–4814.
   PubMed Web of Science ®Google Scholar
• Marchetti V, Krohne TU, Friedlander DF, et al. Stemming vision loss with stem cells. J Clin Invest. 2010;120(9):3012–3021.
   PubMed Web of Science ®Google Scholar
• Vadlapudi AD, Mitra AK. Nanomicelles: an emerging platform for drug delivery to the eye. Ther Deliv. 2013;4(1):1–3.
   PubMedGoogle Scholar
• Iriyama A, Oba M, Ishii T, et al. Gene transfer using micellar nanovectors inhibits choroidal neovascularization in vivo. PLoS One. 2011;6(12):e28560.
   PubMed Web of Science ®Google Scholar
• Ideta R, Yanagi Y, Tamaki Y, et al. Effective accumulation of polyion complex micelle to experimental choroidal neovascularization in rats. FEBS Lett. 2004;557(1–3):21–25.
   PubMed Web of Science ®Google Scholar
• Oh EJ, Choi JS, Kim H, et al. Anti-flt1 peptide - hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy. Biomaterials. 2011;32(11):3115–3123.
   PubMed Web of Science ®Google Scholar
• Kim H, Choi JS, Kim KS, et al. Flt1 peptide-hyaluronate conjugate micelle-like nanoparticles encapsulating genistein for the treatment of ocular neovascularization. Acta Biomater. 2012;8(11):3932–3940.
   PubMed Web of Science ®Google Scholar
• Ing TS, Yu AW, Thompson KD, et al. Peritoneal dialysis using conventional, lactate–containing solution sterilized by ultrafiltration. Int J Artif Organs. 1992;15(11):658–660.
   PubMed Web of Science ®Google Scholar
• Patel A, Cholkar K, Agrahari V, et al. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2(2):47–64.
   PubMedGoogle Scholar
• Lajavardi L, Bochot A, Camelo S, et al. Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal peptide encapsulated in liposomes. Invest Ophthalmol Vis Sci. 2007;48(7):3230–3238.
   PubMed Web of Science ®Google Scholar
• Lajavardi L, Camelo S, Agnely F, et al. New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis. J Controlled Release Off J Controlled Release Soc. 2009;139(1):22–30.
   PubMed Web of Science ®Google Scholar
• Abrishami M, Zarei-Ghanavati S, Soroush D, et al. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina. 2009;29(5):699–703.
   PubMed Web of Science ®Google Scholar
• Baranowski P, Karolewicz B, Gajda M, et al. Ophthalmic drug dosage forms: characterisation and research methods. Sci World J. 2014;2014:1–14.
   Web of Science ®Google Scholar
• Patel SP, Vaishya R, Mishra GP, et al. Tailor-made pentablock copolymer based formulation for sustained ocular delivery of protein therapeutics. J Drug Deliv. 2014;2014:1–15.
   Google Scholar
• Sp P, Vaishya R, Yang X, et al. Novel thermosensitive pentablock copolymers for sustained delivery of proteins in the treatment of posterior segment diseases. Protein Pept Lett. 2014;21(11):1185–1200.
   PubMed Web of Science ®Google Scholar
• Yandrapu SK, Upadhyay AK, Petrash JM, et al. Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab. Mol Pharm. 2013;10(12):4676–4686.
   PubMed Web of Science ®Google Scholar
• Feng L, Li SK, Liu H, et al. Ocular delivery of prna nanoparticles: distribution and clearance after subconjunctival injection. Pharm Res. 2014;31(4):1046–1058.
   PubMed Web of Science ®Google Scholar
• Zulliger R, Conley SM, Naash MI. Non-viral therapeutic approaches to ocular diseases: an overview and future directions. J Controlled Release Off J Controlled Release Soc. 2015;219:471–487.
   PubMed Web of Science ®Google Scholar
• Mitra RN, Han Z, Merwin M, et al. Synthesis and characterization of glycol chitosan DNA nanoparticles for retinal gene delivery. ChemMedChem. 2014;9(1):189–196.
   PubMed Web of Science ®Google Scholar
• Koirala A, Conley SM, Makkia R, et al. Persistence of non-viral vector mediated rpe65 expression: case for viability as a gene transfer therapy for rpe-based diseases. J Controlled Release Off J Controlled Release Soc. 2013;172(3):745–752.
   PubMed Web of Science ®Google Scholar
• Ghassemi AH, Van Steenbergen MJ, Barendregt A, et al. Controlled release of octreotide and assessment of peptide acylation from poly(d,l-lactide-co-hydroxymethyl glycolide) compared to plga microspheres. Pharm Res. 2012;29(1):110–120.
   PubMed Web of Science ®Google Scholar
• Shirangi M, Najafi M, Rijkers DT, et al. Inhibition of octreotide acylation inside plga microspheres by derivatization of the amines of the peptide with a self-immolative protecting group. Bioconjug Chem. 2016;27(3):576–585.
   PubMed Web of Science ®Google Scholar
• Wassmer S, Rafat M, Fong WG, et al. Chitosan microparticles for delivery of proteins to the retina. Acta Biomater. 2013;9(8):7855–7864.
   PubMed Web of Science ®Google Scholar
• Panda JJ, Yandrapu S, Kadam RS, et al. Self-assembled phenylalanine-alpha,beta-dehydrophenylalanine nanotubes for sustained intravitreal delivery of a multi-targeted tyrosine kinase inhibitor. J Controlled Release Off J Controlled Release Soc. 2013;172(3):1151–1160.
   PubMed Web of Science ®Google Scholar
• Wang J, Jiang A, Joshi M, et al. Drug delivery implants in the treatment of vitreous inflammation. Mediators Inflamm. 2013;2013:1–8.
   Web of Science ®Google Scholar
• Sotoodehnejadnematalahi F, Burke B. Human activated macrophages and hypoxia: a comprehensive review of the literature. Iran J Basic Med Sci. 2014;17(11):820–830.
   PubMed Web of Science ®Google Scholar
• Drug delivery to the posterior segment. Available from: http://www.neurotechusa.com/
   Google Scholar
• Madaan K, Kumar S, Poonia N, et al. Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci. 2014;6(3):139–150.
   PubMedGoogle Scholar
• Marano RJ, Toth I, Wimmer N, et al. Dendrimer delivery of an anti-vegf oligonucleotide into the eye: a long-term study into inhibition of laser-induced cnv, distribution, uptake and toxicity. Gene Ther. 2005;12(21):1544–1550.
   PubMed Web of Science ®Google Scholar
• Yavuz B, Pehlivan SB, Unlu N. Dendrimeric systems and their applications in ocular drug delivery. Sci World J. 2013;2013:1–13.
   Web of Science ®Google Scholar
• Jain K, Kesharwani P, Gupta U, et al. Dendrimer toxicity: let’s meet the challenge. Int J Pharm. 2010;394(1–2):122–142.
   PubMed Web of Science ®Google Scholar
• Waite CL, Sparks SM, Uhrich KE, et al. Acetylation of pamam dendrimers for cellular delivery of sirna. BMC Biotechnol. 2009;9:38.
   PubMed Web of Science ®Google Scholar
• Agrawal P, Gupta U, Jain NK. Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials. 2007;28(22):3349–3359.
   PubMed Web of Science ®Google Scholar
• Agashe HB, Dutta T, Garg M, et al. Investigations on the toxicological profile of functionalized fifth-generation poly (propylene imine) dendrimer. J Pharm Pharmacol. 2006;58(11):1491–1498.
   PubMed Web of Science ®Google Scholar
• Stasko NA, Johnson CB, Schoenfisch MH, et al. Cytotoxicity of polypropylenimine dendrimer conjugates on cultured endothelial cells. Biomacromolecules. 2007;8(12):3853–3859.
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Biologic molecules currently in clinical trials for treatment of posterior ocular diseases. Available from: https://clinicaltrials.gov
   Google Scholar
• Clinical Trials. A phase 3 safety and efficacy study of Fovista (E10030). Intravenous administration in combination with Lucentis and compared with Lucentis monotherapy [First received September 2013. Last update September 2015]. Clinical Trials Identifier NCT01940900. Available from: https://clinicaltrials.gov/ct2/show/NCT01940900
   Google Scholar
• Ishikawa M, Jin D, Sawada Y, et al. Future therapies of wet age-related macular degeneration. J Ophthalmol. 2015;2015:1–10.
   Web of Science ®Google Scholar
• Ophthotech Corporation. Fovista, anti-PDGF therapy clinical development in combination with anti-VEGF therapy for treatment of wet AMD. Available from: http://www.ophthotech.com/wp-content/uploads/Fovista_Fact_Sheet.pdf
   Google Scholar
• Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111(9):1287–1295.
   PubMed Web of Science ®Google Scholar
• Dejneka NS, Wan S, Bond OS, et al. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis. 2008;14:997–1005.
   PubMed Web of Science ®Google Scholar
• Shen J, Samul R, Silva RL, et al. Suppression of ocular neovascularization with sirna targeting vegf receptor 1. Gene Ther. 2006;13(3):225–234.
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Symons RC, Shah SM, et al. Rnai-based treatment for neovascular age-related macular degeneration by sirna-027. Am J Ophthalmol. 2010;150(1):33–39.e2.
   Web of Science ®Google Scholar
• Rittenhouse KD, Johnson TR, Vicini P, et al. Rtp801 gene expression is differentially upregulated in retinopathy and is silenced by pf-04523655, a 19-mer sirna directed against rtp801. Invest Ophthalmol Vis Sci. 2014;55(3):1232–1240.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Schachar RA, Nduaka CI, et al. Phase 1 dose-escalation study of a sirna targeting the rtp801 gene in age-related macular degeneration patients. Eye. 2012;26(8):1099–1105.
   PubMed Web of Science ®Google Scholar
• Atram SC, Bobade NN, Wankhade VP, et al. Current trends towards an ocular drug delivery system. Int J Pharm Pharm Sci Res. 2013;3(1):28–34.
   Google Scholar
• Meller D, Thomasen H, Steuhl KP. ocular surface reconstruction in limbal stem cell deficiency: transplantation of cultivated limbal epithelium. Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2012;109(9):863–868.
   PubMed Web of Science ®Google Scholar
• Basu S, Mohamed A, Chaurasia S, et al. Clinical outcomes of penetrating keratoplasty after autologous cultivated limbal epithelial transplantation for ocular surface burns. Am J Ophthalmol. 2011;152(6):917–924, e911.
   PubMed Web of Science ®Google Scholar